Loading...
TRML logo

Tourmaline Bio, Inc.NasdaqGS:TRML Stock Report

Market Cap US$1.2b
Share Price
n/a
1Y81.2%
7D0.02%
1D0%
Portfolio Value
​
View

Tourmaline Bio, Inc.

NasdaqGS:TRML Stock Report

Market Cap: US$1.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tourmaline Bio (TRML) Stock Overview

Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. More details

TRML fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 22.2% per year for the next 3 years

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years


TRML Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,757 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
439,757 investors already sharing narratives
View all narratives

Tourmaline Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tourmaline Bio
Historical stock prices
Current Share PriceUS$47.98
52 Week HighUS$48.27
52 Week LowUS$11.56
Beta1.58
1 Month Change-0.37%
3 Month Change116.81%
1 Year Change81.19%
3 Year Changen/a
5 Year Changen/a
Change since IPO340.18%

Recent News & Updates

Seeking Alpha • Sep 09

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Summary Novartis AG is acquiring Tourmaline Bio, Inc. for $1.4B, recognizing the value of TRML's phase 3-ready IL-6 inhibitor, pacibekitug, for cardiovascular diseases. Pacibekitug demonstrated robust, durable hs-CRP reduction in phase 2, with quarterly dosing offering a unique compliance advantage over competitors. The acquisition provides NVS with a pipeline asset targeting ASCVD, CKD, AAA, and TED, expanding its cardiovascular and inflammation portfolio. Key risks include closing conditions for the buyout and unproven efficacy in upcoming phase 3 and expansion studies, but the clinical thesis remains strong. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Sep 09

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Summary Novartis AG is acquiring Tourmaline Bio, Inc. for $1.4B, recognizing the value of TRML's phase 3-ready IL-6 inhibitor, pacibekitug, for cardiovascular diseases. Pacibekitug demonstrated robust, durable hs-CRP reduction in phase 2, with quarterly dosing offering a unique compliance advantage over competitors. The acquisition provides NVS with a pipeline asset targeting ASCVD, CKD, AAA, and TED, expanding its cardiovascular and inflammation portfolio. Key risks include closing conditions for the buyout and unproven efficacy in upcoming phase 3 and expansion studies, but the clinical thesis remains strong. Read the full article on Seeking Alpha
Analysis Article • Aug 03

Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Apr 19

We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 13

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Summary Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025. Tourmaline Bio had $333.4 million in cash as of June 30th of 2024; Enough cash on hand to fund its operations into 2027. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish

Summary Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 blocker, for thyroid eye disease and atherosclerotic cardiovascular disease. The company's success is uncertain due to competition in the IL-6 inhibitor market and limited efficacy data for TOUR006. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Tourmaline Bio: Time For A Pause

Summary Shares of Tourmaline Bio, Inc. have surged 200% since its public debut in October 2023. The company's main asset, TOUR006, shows potential as a therapy for thyroid eye disease and atherosclerotic cardiovascular disease. Tourmaline is conducting Phase 2 trials for both indications, with competition expected to release Phase 3 data in 2025. Where will the stock go in 2024? A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha

Shareholder Returns

TRMLUS BiotechsUS Market
7D0.02%-5.3%-1.0%
1Y81.2%37.0%14.1%

Return vs Industry: TRML exceeded the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: TRML exceeded the US Market which returned 18.7% over the past year.

Price Volatility

Is TRML's price volatile compared to industry and market?
TRML volatility
TRML Average Weekly Movement17.1%
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: TRML's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TRML's weekly volatility has increased from 12% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
202177Sandeep Kulkarniwww.tourmalinebio.com

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).

Tourmaline Bio, Inc. Fundamentals Summary

How do Tourmaline Bio's earnings and revenue compare to its market cap?
TRML fundamental statistics
Market capUS$1.24b
Earnings (TTM)-US$88.47m
Revenue (TTM)n/a
0.0x
P/S Ratio
-14.0x
P/E Ratio

Is TRML overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRML income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$88.47m
Earnings-US$88.47m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.43
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TRML perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/29 20:34
End of Day Share Price 2025/10/27 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tourmaline Bio, Inc. is covered by 1 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Roger SongJefferies LLC